18702 N. Creek Parkway
Suite 100
Bothell, WA 98011
United States
610-321-3700
https://immunome.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 62
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Clay B. Siegall Ph.D. | President, CEO & Chairman | 1.43M | N/A | 1961 |
Dr. Jack Higgins Ph.D. | Chief Scientific Officer | 956.34k | N/A | 1980 |
Dr. Robert J. Lechleider M.D. | Chief Medical Officer | 512.49k | N/A | 1961 |
Mr. Max Rosett | Executive VP of Operations, Principal Accounting & Financial Officer and CFO | N/A | N/A | 1990 |
Ms. Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel & Corporate Secretary | 443.43k | N/A | 1974 |
Mr. Bruce Turner M.D., Ph.D. | Chief Strategy Officer | N/A | N/A | 1964 |
Mr. Kinney Horn | Chief Business Officer | N/A | N/A | 1975 |
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc.’s ISS governance QualityScore as of 1 June 2024 is 10. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 7; Compensation: 10.